NeoPharm CO. LTD (092730) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NeoPharm CO. LTD (092730) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩5.88 Billion ≈ $3.98 Million USD) by net assets (₩188.40 Billion ≈ $127.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NeoPharm CO. LTD - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how NeoPharm CO. LTD's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NeoPharm CO. LTD (092730) total liabilities for a breakdown of total debt and financial obligations.
NeoPharm CO. LTD Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NeoPharm CO. LTD ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
LUOYANG GLASS CO. H YC 1
F:LUG
|
N/A |
|
Borosil Scientific
NSE:BOROSCI
|
N/A |
|
WW Holding Inc
TW:8442
|
-0.001x |
|
Crosswood
PA:CROS
|
-0.020x |
|
Union Bankshares Inc
NASDAQ:UNB
|
0.125x |
|
Affluent Medical SAS
PA:AFME
|
-0.319x |
|
Nova Klúbburinn hf.
IC:NOVA
|
N/A |
|
SAMYOUNG M-Tek Co. Ltd
KQ:054540
|
0.009x |
Annual Cash Flow Conversion Efficiency for NeoPharm CO. LTD (2012–2024)
The table below shows the annual cash flow conversion efficiency of NeoPharm CO. LTD from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of NeoPharm CO. LTD.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩176.88 Billion ≈ $119.87 Million |
₩18.63 Billion ≈ $12.63 Million |
0.105x | -27.54% |
| 2023-12-31 | ₩160.03 Billion ≈ $108.45 Million |
₩23.26 Billion ≈ $15.76 Million |
0.145x | +13.83% |
| 2022-12-31 | ₩142.21 Billion ≈ $96.37 Million |
₩18.16 Billion ≈ $12.31 Million |
0.128x | -23.25% |
| 2021-12-31 | ₩130.30 Billion ≈ $88.31 Million |
₩21.68 Billion ≈ $14.69 Million |
0.166x | +14.72% |
| 2020-12-31 | ₩117.72 Billion ≈ $79.78 Million |
₩17.07 Billion ≈ $11.57 Million |
0.145x | -20.26% |
| 2019-12-31 | ₩105.69 Billion ≈ $71.63 Million |
₩19.22 Billion ≈ $13.03 Million |
0.182x | -33.35% |
| 2018-12-31 | ₩59.29 Billion ≈ $40.18 Million |
₩16.18 Billion ≈ $10.96 Million |
0.273x | +21.97% |
| 2017-12-31 | ₩47.58 Billion ≈ $32.25 Million |
₩10.65 Billion ≈ $7.21 Million |
0.224x | -5.75% |
| 2016-12-31 | ₩38.57 Billion ≈ $26.14 Million |
₩9.16 Billion ≈ $6.21 Million |
0.237x | +27.07% |
| 2015-12-31 | ₩32.62 Billion ≈ $22.11 Million |
₩6.09 Billion ≈ $4.13 Million |
0.187x | +890.58% |
| 2012-12-31 | ₩29.92 Billion ≈ $20.28 Million |
₩564.34 Million ≈ $382.45K |
0.019x | -- |
About NeoPharm CO. LTD
NeoPharm CO., LTD. manufactures and sells skin care products in South Korea. The company offers Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand; products for sensitive, dry, oily, or trouble-prone skin under the ZEROID brand; body moisturizers under the Derma-B brand; and sport care products for athletes under the MISSION ATHELE… Read more